Reported 22 days ago
Thermo Fisher Scientific Inc. (TMO) has been identified as one of the top innovative healthcare stocks to monitor in 2025, with a significant revenue growth of 5% year-over-year in Q4 2024, totaling $11.4 billion. The company remains profitable with strong cash flow and a history of increasing dividends over eight consecutive years. Analysts are optimistic about TMO due to a recent $4.1 billion acquisition aimed at enhancing its position in the bioprocessing market. Despite its potential, the article suggests that AI stocks may offer greater investment returns in the near future.
Source: YAHOO